Copyright © 2001 by the European Society of Cardiology.
Mutation in the promoter region of the ß-fibrinogen gene and the risk of future myocardial infarction, stroke and venous thrombosis
a The Center for Cardiovascular Disease Prevention, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, U.S.A.
d The Leducq Center for Molecular and Genetic Epidemiology of Cardiovascular Disease, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, U.S.A.
b The Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, U.S.A.
c The Max-Delbruck-Center for Molecular Medicine, Berlin, Germany
revised March 5, 2001; accepted March 7, 2001
Abstract
Aim Polymorphisms in the promoter region of the ß-fibrinogen gene are associated with increased plasma fibrinogen levels. We investigated whether the distribution of the C148T polymorphism is associated with an increase in cardiovascular risk.
Methods and Results In a nested case-control design, the distribution of the C148T polymorphism was investigated among 751 participants in the Physicians' Health Study who subsequently developed myocardial infarction, stroke or venous thromboembolism (cases) and among 751 age- and smoking-matched controls over follow-up of 8·6 years. Frequency of the T allele was similar among men who had myocardial infarction (22·7%, P=0·5), stroke (18·4%, P=0·2) or venous thromboembolism (17·0%, P=0·1) compared with those with no cardiovascular events (21·5%). The relative risk for any vascular event among men homozygous or heterozygous for the T allele compared with men homozygous for the C allele was 0·94 (95% CI 0·76–1·16). We found no evidence of an association between the T allele and myocardial infarction (relative risk 1·06; 95% CI 0·82–1·36), stroke (0·87, 0·63–1·21) or venous thromboembolism (0·75; 0·51–1·08). Analysis adjusted for aspirin use and traditional cardiovascular risk factors had no significant effect on these findings.
Conclusion In a large prospective cohort, carriage of the T allele for the C148T mutation in the ß-fibrinogen promoter gene was not associated with an increased subsequent risk of cardiovascular events.
Key Words: ß-Fibrinogen promoter gene, myocardial infarction, stroke, venous thrombosis, cardiovascular risk
f1 Correspondence: Dr Paul M. Ridker, Center for Cardiovascular Disease Prevention, Brigham and Women's Hospital, 900 Commonwealth Avenue East, Boston, MA 02215, U.S.A.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  I. Parastatidis, L. Thomson, A. Burke, I. Chernysh, C. Nagaswami, J. Visser, S. Stamer, D. C. Liebler, G. Koliakos, H. F. G. Heijnen, et al. Fibrinogen {beta}-Chain Tyrosine Nitration Is a Prothrombotic Risk Factor J. Biol. Chem., December 5, 2008; 283(49): 33846 - 33853. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Koch, P. Hoppmann, J. Biele, J. C. Mueller, A. Schomig, and A. Kastrati Fibrinogen Genes and Myocardial Infarction: A Haplotype Analysis Arterioscler Thromb Vasc Biol, April 1, 2008; 28(4): 758 - 763. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. L. Smith, L. A. Hindorff, S. R. Heckbert, R. N. Lemaitre, K. D. Marciante, K. Rice, T. Lumley, J. C. Bis, K. L. Wiggins, F. R. Rosendaal, et al. Association of Genetic Variations With Nonfatal Venous Thrombosis in Postmenopausal Women JAMA, February 7, 2007; 297(5): 489 - 498. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Keavney, J. Danesh, S. Parish, A. Palmer, S. Clark, L. Youngman, M. Delepine, M. Lathrop, R. Peto, R. Collins, et al. Fibrinogen and coronary heart disease: test of causality by 'Mendelian randomization' Int. J. Epidemiol., August 1, 2006; 35(4): 935 - 943. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. D. Smith, R. Harbord, J. Milton, S. Ebrahim, and J. A.C. Sterne Does Elevated Plasma Fibrinogen Increase the Risk of Coronary Heart Disease?: Evidence from a Meta-Analysis of Genetic Association Studies Arterioscler Thromb Vasc Biol, October 1, 2005; 25(10): 2228 - 2233. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M P J van Goor, E B Gomez-Garcia, F W G Leebeek, G J Brouwers, P J Koudstaal, and D W J Dippel The - 148 C/T fibrinogen gene polymorphism and fibrinogen levels in ischaemic stroke: a case-control study J. Neurol. Neurosurg. Psychiatry, January 1, 2005; 76(1): 121 - 123. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kamath and G.Y.H. Lip Fibrinogen: biochemistry, epidemiology and determinants QJM, October 1, 2003; 96(10): 711 - 729. [Full Text] [PDF]
|
|
|
|
 |
|
 W. H Reinhart Fibrinogen - marker or mediator of vascular disease? Vascular Medicine, August 1, 2003; 8(3): 211 - 216. [Abstract] [PDF]
|
|